Lilly's Tirzepatide Achieves All Primary and Key Secondary Study Outcomes Against Insulin Glargine in Adults with Type 2 Diabetes and Increased Cardiovascular Risk in SURPASS-4 Trial
INDIANAPOLIS, May 20, 2021 /PRNewswire/ -- Tirzepatide led to superior A1C and body weight reductions from baseline across all three doses in adults with type 2 diabetes who have increased cardiovascular (CV) risk compared to titrated... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 20, 2021 Category: Pharmaceuticals Source Type: clinical trials
Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes Insufficiently Controlled by Insulin Glargine and Metformin Combination Therapy
Conditions: Type 2 Diabetes Mellitus; Glucose, High Blood Intervention: Drug: GLP-1 receptor agonist Sponsor: Chungbuk National University Hospital Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 19, 2021 Category: Research Source Type: clinical trials
Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes
Conditions: Type 2 Diabetes Mellitus; Glucose, High Blood Interventions: Drug: IGlarLixi; Drug: Dulaglutide Sponsor: Chungbuk National University Hospital Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 19, 2021 Category: Research Source Type: clinical trials
